Pharma News - Drug Trials News & Articles

161 FDA Advisory Committee recommends approval of BREO ELLIPT for the treatment of COPD Full Text GlaxoSmithKline, April 19, 2013

162 Phase I trial of capecitabine rapidly disintegrating tablets and concomitant radiation therapy in children with newly diagnosed brainstem gliomas and high-grade gliomas Neuro-Oncology, April 19, 2013    Review Article

163 Bayer Initiates Phase III Trial of Investigational Inhaled Amikacin Solution (BAY41-6551) in Mechanically Ventilated Patients with Gram-negative Pneumonia Full Text Bayer HealthCare Pharmaceuticals, April 19, 2013

164 Teva Presented New Data from Phase III Clinical Trial of Milprosa (Progesterone) Vaginal Ring at the 61st Annual Meeting of the Pacific Coast Reproductive Society Full Text Teva Pharmaceutical Industries, April 19, 2013

165 Sarepta Therapeutics Announces FDA Will Consider Accelerated Approval for Eteplirsen After Further Review of Data on Dystrophin and Clinical Outcomes Full Text Sarepta Therapeutics, April 19, 2013

166 Array BioPharma Announces Updates on ARRY-520 Clinical Data at the 2013 International Myeloma Workshop Full Text Array BioPharma, April 19, 2013

167 FDA Releases Guidance on Non-Penicillin Beta-Lactam Drugs Full Text BioPharm International, April 18, 2013

168 Spherix Announces Positive Phase 2 Study Results Full Text Spherix, April 18, 2013

169 Translating Stem Cells From Laboratory to Clinic Full Text BioPharm International, April 18, 2013

170 Salinomycin Induces Apoptosis via Death Receptor-5 Up-regulation in Cisplatin-resistant Ovarian Cancer Cells Anticancer Research, April 18, 2013    Clinical Article

171 Almirall and Forest Laboratories Announce Positive Phase III Study Results for Aclidinium and Formoterol Combination in COPD Full Text Forest Laboratories, April 17, 2013

172 Mylan Delivers Much-anticipated One Pill Once a Day Triple Fixed-dose Antiretroviral Combination to the South African National Department of Health Full Text Mylan, April 17, 2013

173 Improved CD4+ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: A randomized trial Vaccine , April 16, 2013    Review Article

174 Pfizer's Palbociclib (PD-0332991) Receives Food And Drug Administration Breakthrough Therapy Designation For Potential Treatment Of Patients With Breast Cancer Full Text Pfizer, April 15, 2013

175 Early Results of Activartis AV0113 Cancer Immunotherapy in Glioblastoma Trial Reveal Promising Trend Full Text B3C newswire, April 12, 2013

176 EyeGates EGP-437 Matches the Standard-of-Cares Response Rate in Phase III Study of Patients with Anterior Uveitis Full Text EyeGate Pharma, April 11, 2013

177 ImmunoGen, Inc. Announces Preclinical Findings with its IMGN289 Product Candidate for the Treatment of EGFR-Overexpressing Cancers Full Text ImmunoGen, Inc., April 11, 2013

178 Bortezomib, dexamethasone plus thalidomide for treatment of newly diagnosed multiple myeloma patients with or without renal impairment Full Text Chinese Journal of Cancer Research, April 11, 2013    Clinical Article

179 Sarepta Therapeutics Announces Eteplirsen Demonstrates Sustained Benefit on Walking Test Through 74 Weeks in Phase IIb Study in Duchenne Muscular Dystrophy Full Text Sarepta Therapeutics, April 10, 2013

180 New Data Show Azilect (rasagiline tablets) Provided Clinical Benefit in Patients with Early Parkinsons When Added to Sub-Optimally Controlled Patients on Dopamine Agonist Therapy Full Text Teva Pharmaceutical Industries, April 10, 2013

1 Statement on FOSAMAX (alendronate sodium) Product Liability Trial Merck, March 12, 2013    Free full text

2 Teva Presented New Data from Phase III Clinical Trial of Milprosa (Progesterone) Vaginal Ring at the 61st Annual Meeting of the Pacific Coast Reproductive Society Teva Pharmaceutical Industries, April 22, 2013    Free full text

3 CEL-SCI Corporation Provides Update on Phase III Clinical Trial CEL-SCI, April 24, 2013    Free full text

4 FDA Releases Guidance on Non-Penicillin Beta-Lactam Drugs BioPharm International, April 18, 2013    Free full text

5 Merck Provides Update on IMPROVE-IT Trial Merck, March 13, 2013    Free full text

6 Pfizer's Palbociclib (PD-0332991) Receives Food And Drug Administration Breakthrough Therapy Designation For Potential Treatment Of Patients With Breast Cancer Pfizer, April 15, 2013    Free full text

7 Merck Pays $688 Million to Resolve Vytorin Lawsuits BioPharm International, February 28, 2013    Free full text

8 Phase Ib Dose-Escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma Clinical Cancer Research, April 8, 2013

9 FDA Approves New Drug Application (NDA) for Tevas Quartette- (levonorgestrel/ethinyl estradiol and ethinyl estradiol) Tablets for the Prevention of Pregnancy Teva Pharmaceutical Industries, April 1, 2013    Free full text

10 Interim results evaluate virologic response rates in HCV/HIV co-infected patients treated with faldaprevir Formulary , March 21, 2013    Free full text

11 New Data Show Azilect (rasagiline tablets) Provided Clinical Benefit in Patients with Early Parkinsons When Added to Sub-Optimally Controlled Patients on Dopamine Agonist Therapy Teva Pharmaceutical Industries, March 21, 2013    Free full text

12 Improving IRBs: A Case Study with Copernicus Group IRB Applied Clinical Trials, March 28, 2013    Free full text

13 BioMarin Submits Vimizim MAA to EMA for the Treatment of MPS IVA BioMarin, April 25, 2013    Free full text

14 Beyond Statins: Lipid Management to Reduce Cardiovascular Risk Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, April 26, 2013    Evidence Based Medicine    Review Article

15 PhRMA Statement on Clinical Trials and Bad Pharma PhRMA, February 7, 2013    Free full text

16 Sarepta Therapeutics Announces FDA Will Consider Accelerated Approval for Eteplirsen After Further Review of Data on Dystrophin and Clinical Outcomes Sarepta Therapeutics, April 19, 2013    Free full text

17 Translating Stem Cells From Laboratory to Clinic BioPharm International, April 18, 2013    Free full text

18 Do patients with metastatic urothelial carcinoma benefit from docetaxel as second-line chemotherapy Clinical and Translational Oncology, April 24, 2013

19 Modified DCF (mDCF) regimen seems to be as effective as original DCF in advanced gastric cancer (AGC) Clinical and Translational Oncology, April 29, 2013

20 Sarepta Therapeutics Announces Eteplirsen Demonstrates Sustained Benefit on Walking Test Through 74 Weeks in Phase IIb Study in Duchenne Muscular Dystrophy Sarepta Therapeutics, April 10, 2013    Free full text